Liver is a Target of Arsenic Carcinogenesis
Open Access
- 19 June 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 105 (1), 24-32
- https://doi.org/10.1093/toxsci/kfn120
Abstract
Inorganic arsenic is clearly a human carcinogen causing tumors of the skin, lung, urinary bladder, and possibly liver (IARC, 2004). At the time of construction of this monograph, the evidence for arsenic as a hepatocarcinogen in humans was considered controversial and in rodents considered insufficient. However, recent data has accumulated indicating hepatocarcinogenicity of arsenic. This forum reevaluates epidemiology studies, rodent studies together with in vitro models, and focuses on the liver as a target organ of arsenic toxicity and carcinogenesis. Hepatocellular carcinoma and hepatic angiosarcoma, have been frequently associated with environmental or medicinal exposure to arsenicals. Preneoplastic lesions, including hepatomegaly, hepatoportal sclerosis, fibrosis, and cirrhosis often occur after chronic arsenic exposure. Recent work in mice clearly shows that exposure to inorganic arsenic during gestation induces tumors, including hepatocellular adenoma and carcinoma, in offspring when they reach adulthood. In rats, the methylated arsenicals, dimethylarsinic acid promotes diethylnitrosamine-initiated liver tumors, whereas trimethylarsine oxide induces liver adenomas. Chronic exposure of rat liver epithelial cells to low concentrations of inorganic arsenic induces malignant transformation, producing aggressive, undifferentiated epithelial tumors when inoculated into the Nude mice. There are a variety of potential mechanisms for arsenical-induced hepatocarcinogenesis, such as oxidative DNA damage, impaired DNA damage repair, acquired apoptotic tolerance, hyperproliferation, altered DNA methylation, and aberrant estrogen signaling. Some of these mechanisms may be liver specific/selective. Overall, accumulating evidence clearly indicates that the liver could be an important target of arsenic carcinogenesis.Keywords
This publication has 67 references indexed in Scilit:
- Transplacental arsenic carcinogenesis in miceToxicology and Applied Pharmacology, 2007
- Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenicToxicology, 2007
- Transplacental exposure to inorganic arsenic at a hepatocarcinogenic dose induces fetal gene expression changes in mice indicative of aberrant estrogen signaling and disrupted steroid metabolismToxicology and Applied Pharmacology, 2007
- Long term low-dose arsenic exposure induces loss of DNA methylationBiochemical and Biophysical Research Communications, 2007
- Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liverJournal of Hepatology, 2006
- Liver tumorigenicity of trimethylarsine oxide in male Fischer 344 rats--association with oxidative DNA damage and enhanced cell proliferationCarcinogenesis: Integrative Cancer Research, 2003
- Mortality for Certain Diseases in Areas with High Levels of Arsenic in Drinking WaterArchives of environmental health, 1999
- Arsenic and non-cirrhotic portal hypertension: A report of eight casesJournal of Hepatology, 1990
- Levels of arsenic in liver cirrhosisToxicology Letters, 1983
- Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India.Gut, 1979